Tag: Skin Disorders: Misc.
Cutaneous AEs Linked to Immune Checkpoint Inhibitor Therapy
Cutaneous immune-related adverse events seen in 25 percent of cancer patients initiating ICI therapy with median onset time of 113 days
Delayed Local Reactions to mRNA-1273 Vaccination Reported
Reactions appeared near injection site at a median onset of day 8 after first dose; six of 12 patients had no recurrence after second dose
Cutaneous Findings Described for Children With MIS-C
Cutaneous findings varied among patients; annular plaques in the proximal medial lower extremities were common
Tirbanibulin Superior to Placebo for Actinic Keratosis
Significantly more patients treated with tirbanibulin had complete clearance of lesions at day 57
Dermatology Patients Pleased With Telehealth Options
Patients report telehealth consultations are safe and efficient during the COVID-19 pandemic
Chilblain-Like Lesions During COVID-19 Tied to Type I Interferonopathy
Findings based on systematic clinical, histologic, and biologic assessment
Irritated Skin Tied to Pressure Injuries in Critical Care Patients
Treating, monitoring irritated skin may prevent pressure injuries
Dermatologic Manifestations of COVID-19 May Persist
Papulosquamous eruptions, pernio/chilblains last ≥60 days in some patients
Switching Skin Antiseptics Could Reduce Surgical Site Infections
